Good News From Kimia Farma, Sinopharm Booster Vaccine Certificate Now Available On PeduliLindung Application

Illustration of booster vaccination. (Photo: Doc. Antara)

JAKARTA - The certificate for the Sinopharm booster vaccine is available and can be accessed by the public on the PeduliLindung application.

This assurance was conveyed by the President Director of PT Kimia Farma (Persero) Tbk Verdi Budidarmo.

"This follow-up vaccine or Sinopharm booster is here to help accelerate the vaccination program that has been launched by the government and after the booster with Sinopharm has been carried out. Certificates for further doses or booster vaccines can be accessed at Peduli Protect," Verdi said in a statement quoted by Antara, Wednesday, 16 February.

Sinopharm vaccine has received Emergency Use Authorization (EUA) or emergency approval from the Food and Drug Supervisory Agency (BPOM) as a homologous follow-up or booster vaccine for adults 18 years and over.

Thus, people who have received the complete primary dose of Sinopharm vaccine for at least 6 months can receive this booster vaccine produced by the Beijing Bio-Institute Biological.

"For the implementation of a follow-up or booster vaccination with the Sinopharm Vaccine, 350 Kimia Farma clinics spread throughout Indonesia are ready to carry out a follow-up or booster vaccination with the Sinopharm vaccine," said Verdi.

BPOM has evaluated the efficacy and safety aspects referring to the COVID-19 vaccine evaluation standard for the Sinopharm vaccine as a homologous booster dose for adults 18 years and over.

The Sinopharm vaccine as a booster is generally well tolerated. The frequency, type, and severity of adverse reactions or adverse events (KTD) after booster administration was lower than during primary dosing.

The adverse events that often occur are local reactions such as pain at the injection site, swelling, and redness as well as systemic reactions such as headache, fatigue, and muscle pain, with a severity grade of 1–2.

Judging from the immunogenicity aspect, the increase in humoral immune response for the measurement parameters of neutralizing and anti-IgG antibodies was 8.4 times and 8 times, respectively, compared to before giving the booster. The immune response after giving this booster is higher than the immune response produced during primary vaccination.

With the issuance of the Sinopharm Emergency Use Authorization as a homolog booster, people who have received the primary dose of Sinopharm Covid-19 vaccine through legal entities or business entities.